What is Cadrenal Therape's earnings per share (EPS)?

Cadrenal Therape (CVKD) reported diluted earnings per share of $-6.64 for fiscal year 2025. This represents a 23.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cadrenal Therape Financials

CVKD

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Cadrenal Therape (CVKD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 32/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Cadrenal Therape has an operating margin of -6.7%, meaning the company retains $-7 of operating profit per $100 of revenue. This below-average margin results in a low score of 7/100, suggesting thin profitability after operating expenses.

Leverage

Cadrenal Therape carries a low D/E ratio of 0.58, meaning only $0.58 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Cadrenal Therape's current ratio of 2.72 indicates adequate short-term liquidity, earning a score of 51/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Cadrenal Therape generated -$12.6M in operating cash flow, capex of $5K consumed most of it, leaving -$12.6M in free cash flow. This results in a low score of 9/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Cadrenal Therape generates a -483.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -143.2% the prior year.

Piotroski F-Score Weak

1/9

Cadrenal Therape passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.95x

For every $1 of reported earnings, Cadrenal Therape generates $0.95 in operating cash flow (-$12.6M OCF vs -$13.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$200.0M

Cadrenal Therape generated $200.0M in revenue in fiscal year 2025.

EBITDA

-$13.5M

YoY-22.8%

Cadrenal Therape's EBITDA was -$13.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 22.8% from the prior year.

Net Income

-$13.2M

YoY-24.3%

Cadrenal Therape reported -$13.2M in net income in fiscal year 2025. This represents a decrease of 24.3% from the prior year.

EPS (Diluted)

$-6.64

YoY+23.9%

Cadrenal Therape earned $-6.64 per diluted share (EPS) in fiscal year 2025. This represents an increase of 23.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$12.6M

YoY-71.2%

Cadrenal Therape generated -$12.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 71.2% from the prior year.

Cash & Debt

$4.0M

YoY-60.0%

Cadrenal Therape held $4.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

$16.50

YoY+0.0%

Cadrenal Therape paid $16.50 per share in dividends in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Shares Outstanding

YoY+40.6%

Cadrenal Therape had 3M shares outstanding in fiscal year 2025. This represents an increase of 40.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-6.7%

Cadrenal Therape's operating margin was -6.7% in fiscal year 2025, reflecting core business profitability.

Net Margin

-6.6%

Cadrenal Therape's net profit margin was -6.6% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

-483.3%

YoY-340.2pp

Cadrenal Therape's ROE was -483.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 340.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$4.1M

YoY-2.5%

Cadrenal Therape invested $4.1M in research and development in fiscal year 2025. This represents a decrease of 2.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5K

YoY-21.9%

Cadrenal Therape invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 21.9% from the prior year.

CVKD Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	$200.0M	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	$220K	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	$4.1M-2.5%	$4.2M+3.0%	$4.1M+938.9%	$393K
SG&A Expenses	$9.4M+38.5%	$6.8M+90.3%	$3.5M+53.8%	$2.3M
Operating Income	-$13.5M-22.8%	-$11.0M-43.6%	-$7.6M-182.5%	-$2.7M
Interest Expense	N/A	N/A	$4K-91.2%	$40K
Income Tax	N/A	N/A	N/A	N/A
Net Income	-$13.2M-24.3%	-$10.7M-27.5%	-$8.4M-24.5%	-$6.7M
EPS (Diluted)	$-6.64+23.9%	$-8.73+6.0%	$-9.29	$-0.85

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$688K-36.1%	$1.1M-35.4%	$1.7M	N/A	$785K-37.4%	$1.3M+99.3%	$629K	N/A
SG&A Expenses	$2.0M-23.0%	$2.7M+17.8%	$2.3M	N/A	$1.7M+38.1%	$1.2M+7.7%	$1.1M	N/A
Operating Income	-$2.7M+26.8%	-$3.7M+4.9%	-$3.9M	N/A	-$2.5M+0.3%	-$2.5M-40.5%	-$1.8M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.7M+26.8%	-$3.7M+4.6%	-$3.8M	N/A	-$2.4M-0.6%	-$2.4M-43.9%	-$1.7M	N/A
EPS (Diluted)	$-1.31+29.9%	$-1.87+10.5%	$-2.09	N/A	$-2.18	$-2.24-43.6%	$-1.56	N/A

CVKD Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$4.3M-57.3%	$10.1M+18.8%	$8.5M+994.8%	$778K
Current Assets	$4.3M-57.3%	$10.1M+19.1%	$8.5M+1067.2%	$728K
Cash & Equivalents	$4.0M-60.0%	$10.0M+19.2%	$8.4M+25685.6%	$33K
Inventory	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$1.6M-40.8%	$2.7M+224.6%	$827K-86.9%	$6.3M
Current Liabilities	$1.6M-40.8%	$2.7M+224.6%	$827K-38.0%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$2.7M-63.2%	$7.4M-3.3%	$7.7M+238.6%	-$5.6M
Retained Earnings	-$39.0M-51.5%	-$25.7M-70.7%	-$15.1M-124.5%	-$6.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$4.1M-31.6%	$6.0M-24.8%	$8.0M-21.4%	$10.1M+116.3%	$4.7M-14.3%	$5.5M-22.6%	$7.0M-17.3%	$8.5M
Current Assets	$4.1M-31.7%	$6.0M-24.8%	$7.9M-21.4%	$10.1M+116.4%	$4.7M-14.2%	$5.4M-22.5%	$7.0M-17.2%	$8.5M
Cash & Equivalents	$3.9M-30.7%	$5.6M-24.1%	$7.3M-26.8%	$10.0M+129.6%	$4.4M-13.4%	$5.0M-23.3%	$6.6M-21.9%	$8.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M-19.5%	$1.7M-8.7%	$1.8M-31.4%	$2.7M+111.8%	$1.3M-13.5%	$1.5M+71.1%	$856K+3.6%	$827K
Current Liabilities	$1.4M-19.5%	$1.7M-8.7%	$1.8M-31.4%	$2.7M+111.8%	$1.3M-13.5%	$1.5M+71.1%	$856K+3.6%	$827K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.7M-36.4%	$4.3M-29.7%	$6.1M-17.8%	$7.4M+118.0%	$3.4M-14.5%	$4.0M-35.5%	$6.2M-19.5%	$7.7M
Retained Earnings	-$35.9M-8.1%	-$33.2M-12.4%	-$29.6M-14.9%	-$25.7M-19.4%	-$21.5M-12.6%	-$19.1M-14.3%	-$16.7M-11.0%	-$15.1M

CVKD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	-$12.6M-71.3%	-$7.4M-108.4%	-$3.5M-193.0%	-$1.2M
Capital Expenditures	$5K-21.9%	$7K+100.9%	$3K+42.8%	$2K
Free Cash Flow	-$12.6M-71.2%	-$7.4M-108.4%	-$3.5M-192.7%	-$1.2M
Investing Cash Flow	-$5K+21.9%	-$7K-100.9%	-$3K-42.8%	-$2K
Financing Cash Flow	$6.6M-26.5%	$9.0M-24.6%	$11.9M+860.2%	$1.2M
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.4M+22.1%	-$3.0M+34.9%	-$4.6M-159.6%	-$1.8M+18.6%	-$2.2M-43.9%	-$1.5M+16.7%	-$1.8M-164.4%	-$694K
Capital Expenditures	$2K	$0-100.0%	$3K	N/A	N/A	N/A	N/A	$0
Free Cash Flow	-$2.4M+22.0%	-$3.0M+35.0%	-$4.7M	N/A	N/A	N/A	N/A	-$694K
Investing Cash Flow	-$2K	$0+100.0%	-$3K	N/A	N/A	N/A	N/A	$0
Financing Cash Flow	$648K-48.6%	$1.3M-36.0%	$2.0M-73.6%	$7.5M+387.7%	$1.5M	$0-100.0%	$298+102.4%	-$13K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CVKD Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	-6.7%	N/A	N/A	N/A
Net Margin	-6.6%	N/A	N/A	N/A
Return on Equity	-483.3%-340.2pp	-143.2%-34.5pp	-108.6%	N/A
Return on Assets	-305.9%-200.7pp	-105.2%-7.1pp	-98.1%+764.7pp	-862.8%
Current Ratio	2.72-1.0	3.77-6.5	10.27+9.7	0.55
Debt-to-Equity	0.58+0.2	0.36+0.3	0.11+1.2	-1.14
FCF Margin	-6.3%	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-98.2%-12.9pp	-85.3%-22.4pp	-62.9%	N/A	-70.6%-10.6pp	-59.9%-33.1pp	-26.9%	N/A
Return on Assets	-65.7%-4.4pp	-61.3%-13.0pp	-48.4%	N/A	-51.5%-7.6pp	-43.9%-20.3pp	-23.6%	N/A
Current Ratio	3.02-0.5	3.56-0.8	4.32+0.5	3.77+0.1	3.69-0.0	3.72-4.5	8.21-2.1	10.27
Debt-to-Equity	0.49+0.1	0.39+0.1	0.30-0.1	0.36-0.0	0.370.0	0.37+0.2	0.14+0.0	0.11
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Tenax Therapeutics Inc TENX

$258.2M

Allarity ALLR

$18.7M

Neurosense Therapeutics Ltd NRSN

$27.7M

Dare Bioscience Inc DARE

$25.3M

Neuphoria Therapeutics Inc NEUP

$23.8M

Frequently Asked Questions

What is Cadrenal Therape's annual revenue?

Cadrenal Therape (CVKD) reported $200.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Cadrenal Therape profitable?

No, Cadrenal Therape (CVKD) reported a net income of -$13.2M in fiscal year 2025, with a net profit margin of -6.6%.

What is Cadrenal Therape's EBITDA?

Cadrenal Therape (CVKD) had EBITDA of -$13.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Cadrenal Therape's operating margin?

Cadrenal Therape (CVKD) had an operating margin of -6.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Cadrenal Therape's net profit margin?

Cadrenal Therape (CVKD) had a net profit margin of -6.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Cadrenal Therape pay dividends?

Yes, Cadrenal Therape (CVKD) paid $16.50 per share in dividends during fiscal year 2025.

What is Cadrenal Therape's return on equity (ROE)?

Cadrenal Therape (CVKD) has a return on equity of -483.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cadrenal Therape's free cash flow?

Cadrenal Therape (CVKD) generated -$12.6M in free cash flow during fiscal year 2025. This represents a -71.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cadrenal Therape's operating cash flow?

Cadrenal Therape (CVKD) generated -$12.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Cadrenal Therape's total assets?

Cadrenal Therape (CVKD) had $4.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cadrenal Therape's capital expenditures?

Cadrenal Therape (CVKD) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Cadrenal Therape spend on research and development?

Cadrenal Therape (CVKD) invested $4.1M in research and development during fiscal year 2025.

How many shares does Cadrenal Therape have outstanding?

Cadrenal Therape (CVKD) had 3M shares outstanding as of fiscal year 2025.

What is Cadrenal Therape's current ratio?

Cadrenal Therape (CVKD) had a current ratio of 2.72 as of fiscal year 2025, which is generally considered healthy.

What is Cadrenal Therape's debt-to-equity ratio?

Cadrenal Therape (CVKD) had a debt-to-equity ratio of 0.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cadrenal Therape's return on assets (ROA)?

Cadrenal Therape (CVKD) had a return on assets of -305.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cadrenal Therape's cash runway?

Based on fiscal year 2025 data, Cadrenal Therape (CVKD) had $4.0M in cash against an annual operating cash burn of $12.6M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Cadrenal Therape's Piotroski F-Score?

Cadrenal Therape (CVKD) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cadrenal Therape's earnings high quality?

Cadrenal Therape (CVKD) has an earnings quality ratio of 0.95x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Cadrenal Therape?

Cadrenal Therape (CVKD) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.